Peptides and their potential role in the treatment of diabetes and obesity

Review of Diabetic Studies

Volumn 8, Issue 3, 2011, Pages 355-368

  Greenwood, Hannah C ^a   Bloom, Stephen R ^a   Murphy, Kevin G ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Gastrointestinal hormone; Hypothalamus; Neuropeptide; Obesity; Type 2 diabetes

Indexed keywords

2 [1 (3 CHLORO 5 ISOPROPOXYCARBONYLAMINOPHENYL)ETHYLAMINO] 6 [2 (5 ETHYL 4 METHYL 2 THIAZOLYL)ETHYL] 4 MORPHOLINOPYRIDINE; AMYLIN; BMS 193885; CILIARY NEUROTROPHIC FACTOR; GHRELIN; MELANIN CONCENTRATING HORMONE; MELANOCORTIN; MELANOTAN II; MK 0557; NEUROMEDIN U; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; PEPTIDE HORMONE ANTAGONIST; SNAP 7941; UNCLASSIFIED DRUG; VELNEPERIT;

ARCUATE NUCLEUS; BRAIN STEM; DIABETES MELLITUS; DRUG ANTAGONISM; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; ENERGY BALANCE; FOOD INTAKE; HOMEOSTASIS; HORMONE ACTION; HUMAN; HYPOTHALAMUS; HYPOTHALAMUS NUCLEUS; NONHUMAN; OBESITY; PEPTIDERGIC NERVOUS SYSTEM; PHARMACOLOGICAL BLOCKING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; WEIGHT REDUCTION;

EID: 84856023000     PISSN: 16136071     EISSN: 16140575     Source Type: Journal    
DOI: 10.1900/RDS.2011.8.355     Document Type: Review

References (128)

1. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang YH, Stevens GA, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011. 378(9785):31-40.
2. WHO. Obesity and overweight. 2011.
3. Harris RB, Kasser TR, Martin RJ. Dynamics of recovery of body composition after overfeeding, food restriction or starvation of mature female rats. J Nutr 1986. 116(12):2536-2546.
4. Kalra SP, Dube MG, Pu S, Xu B, Horvath TL, Kalra PS. Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr Rev 1999. 20(1): 68-100.
5. Broberger C, Landry M, Wong H, Walsh JN, Hokfelt T. Subtypes Y1 and Y2 of the neuropeptide Y receptor are respectively expressed in pro-opiomelanocortin-and neuropeptide-Y-containing neurons of the rat hypothalamic arcuate nucleus. Neuroendocrinology 1997. 66(6):393-408.
6. Hahn TM, Breininger JF, Baskin DG, Schwartz MW. Coexpression of Agrp and NPY in fasting-activated hypothalamic neurons. Nat Neurosci 1998. 1(4):271-272.
7. Chronwall BM, DiMaggio DA, Massari VJ, Pickel VM, Ruggiero DA, O'Donohue TL. The anatomy of neuropeptide-Y-containing neurons in rat brain. Neuroscience 1985. 15(4):1159-1181.
8. Morris BJ. Neuronal localisation of neuropeptide Y gene expression in rat brain. J Comp Neurol 1989. 290(3): p. 358-68.
9. Willesen MG, Kristensen P, Romer J. Co-localization of growth hormone secretagogue receptor and NPY mRNA in the arcuate nucleus of the rat. Neuroendocrinology 1999. 70(5):306-316.
10. Baskin DG, Schwartz MW, Seeley RJ, Woods SC, Porte D Jr, Breininger JF, Jonak Z, Schaefer J, Krouse M, Burghardt C, et al. Leptin receptor longform splice-variant protein expression in neuron cell bodies of the brain and co-localization with neuropeptide Y mRNA in the arcuate nucleus. J Histochem Cytochem 1999. 47(3):353-362.
11. Baskin DG, Breininger JF, Schwartz MW. Leptin receptor mRNA identifies a subpopulation of neuropeptide Y neurons activated by fasting in rat hypothalamus. Diabetes 1999. 48(4):828-833.
12. Qian S, Chen H, Weingarth D, Trumbauer ME, Novi DE, Guan X, Yu H, Shen Z, Feng Y, Frazier E, et al. Neither agouti-related protein nor neuropeptide Y is critically required for the regulation of energy homeostasis in mice. Mol Cell Biol 2002. 22(14):5027-5035.
13. Pedrazzini T, Seydoux J, Kunstner P, Aubert JF, Grouzmann E, Beermann F, Brunner HR. Cardiovascular response, feeding behavior and locomotor activity in mice lacking the NPY Y1 receptor. Nat Med 1998. 4(6):722-726.
14. Marsh DJ, Hollopeter G, Kafer KE, Palmiter RD. Role of the Y5 neuropeptide Y receptor in feeding and obesity. Nat Med 1998. 4(6):718-721.
15. Bewick GA, Gardiner JV, Dhillo WS, Kent AS, White NE, Webster Z, Ghatei MA, Bloom SR. Postembryonic ablation of AgRP neurons in mice leads to a lean, hypophagic phenotype. FASEB J 2005. 19(12): 1680-1682.
16. Gropp E, Shanabrough M, Borok E, Xu AW, Janoschek R, Buch T, Plum L, Balthasar N, Hampel B, Waisman A, et al. Agouti-related peptide-expressing neurons are mandatory for feeding. Nat Neurosci 2005. 8(10):1289-1291.
17. Luquet S, Perez FA, Hnasko TS, Palmiter RD. NPY/AgRP neurons are essential for feeding in adult mice but can be ablated in neonates. Science 2005. 310(5748):683-685.
18. Kameda M, Kobayashi K, Ito H, Miyazoe H, Tsujino T, Nakama C, Kawamoto H, Ando M, Ito S, Suzuki T, et al. Optimization of a series of 2,4-diaminopyridines as neuropeptide Y Y1 receptor antagonists with reduced hERG activity. Bioorg Med Chem Lett 2009. 19(15):4325-4329.
19. Antal-Zimanyi I, Bruce MA, Leboulluec KL, Iben LG, Mattson GK, McGovern RT, Hogan JB, Leahy CL, Flowers SC, Stanley JA, et al. Pharmacological characterization and appetite suppressive properties of BMS-193885, a novel and selective neuropeptide Y(1) receptor antagonist. Eur J Pharmacol 2008. 590(1-3):224-232.
20. Kanatani A, Hata M, Mashiko S, Ishihara A, Okamoto O, Haga Y, Ohe T, Kanno T, Murai N, Ishii Y, et al. A typical Y1 receptor regulates feeding behaviors: effects of a potent and selective Y1 antagonist, J-115814. Mol Pharmacol 2001. 59(3):501-505.
21. Mashiko S, Moriya R, Ishihara A, Gomori A, Matsushita H, Egashira S, Iwaasa H, Takahashi T, Haga Y, Fukami T, et al. Synergistic interaction between neuropeptide Y1 and Y5 receptor pathways in regulation of energy homeostasis. Eur J Pharmacol 2009. 615(1-3):113-117.
22. Yulyaningsih E, Zhang L, Herzog H, Sainsbury A. NPY receptors as potential targets for anti-obesity drug development. Br J Pharmacol 2011. 163(6):1170-1202.
23. Erondu N, Gantz I, Musser B, Suryawanshi S, Mallick M, Addy C, Cote J, Bray G, Fujioka K, Bays H, et al. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab 2006. 4(4):275-282.
24. Cone RD. Anatomy and regulation of the central melanocortin system. Nat Neurosci 2005. 8(5):571-578.
25. Cone RD, Lu D, Koppula S, Vage DI, Klungland H, Boston B, Chen W, Orth DN, Pouton C, Kesterson RA. The melanocortin receptors: agonists, antagonists, and the hormonal control of pigmentation. Recent Prog Horm Res 1996. 51:287-317.
26. Brady LS, Smith MA, Gold PW, Herkenham M. Altered expression of hypothalamic neuropeptide mRNAs in food-restricted and food-deprived rats. Neuroendocrinology 1990. 52(5):441-447.
27. Poggioli R, Vergoni AV, Bertolini A. ACTH-(1-24) and alpha-MSH antagonize feeding behavior stimulated by kappa opiate agonists. Peptides 1986. 7(5):843-848.
28. Tsujii S, Bray GA. Acetylation alters the feeding response to MSH and beta-endorphin. Brain Res Bull 1989. 23(3):165-169.
29. Brown KS, Gentry RM, Rowland NE. Central injection in rats of alpha-melanocyte-stimulating hormone analog: effects on food intake and brain Fos. Regul Pept 1998. 78(1-3):89-94.
30. Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR, Gu W, Kesterson RA, Boston BA, Cone RD, et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 1997. 88(1):131-141.
31. Yaswen L, Diehl N, Brennan MB, Hochgeschwender U. Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. Nat Med 1999. 5(9):1066-1070.
32. Butler AA, Kesterson RA, Khong K, Cullen MJ, Pelleymounter MA, Dekoning J, Baetscher M, Cone RD. A unique metabolic syndrome causes obesity in the melanocortin-3 receptor-deficient mouse. Endocrinology 2000. 141(9):3518-3521.
33. Chen AS, Marsh DJ, Trumbauer ME, Frazier EG, Guan XM, Yu H, Rosenblum CI, Vongs A, Feng Y, Cao L, et al. Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. Nat Genet 2000. 26(1):97-102.
34. Fan W, Boston BA, Kesterson RA, Hruby VJ, Cone RD. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature 1997. 385(6612):165-168.
35. Chen AS, Metzger JM, Trumbauer ME, Guan XM, Yu H, Frazier EG, Marsh DJ, Forrest MJ, Gopal-Truter S, Fisher J, et al. Role of the melanocortin-4 receptor in metabolic rate and food intake in mice. Transgenic Res 2000. 9(2):145-154.
36. Koegler FH, Grove KL, Schiffmacher A, Smith MS, Cameron JL. Central melanocortin receptors mediate changes in food intake in the rhesus macaque. Endocrinology 2001. 142(6):2586-2592.
37. Farooqi IS, Yeo GS, Keogh JM, Aminian S, Jebb SA, Butler G, Cheetham T, O'Rahilly S. Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. J Clin Invest 2000. 106(2):271-279.
38. Vaisse C, Clement K, Durand E, Hercberg S, Guy-Grand B, Froguel P. Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J Clin Invest 2000. 106(2):253-262.
39. Krude H, Biebermann H, Luck W, Horn R, Brabant G, Gruters A. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 1998. 19(2):155-157.
40. Jackson RS, Creemers JW, Ohagi S, Raffin-Sanson ML, Sanders L, Montague CT, Hutton JC, O'Rahilly S. Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene. Nat Genet 1997. 16(3):303-306.
41. Lee YS, Poh LK, Kek BL, Loke KY. The role of melanocortin 3 receptor gene in childhood obesity. Diabetes 2007. 56(10):2622-2630.
42. Fehm HL, Smolnik R, Kern W, McGregor GP, Bickel U, Born J. The melanocortin melanocytestimulating hormone/adrenocorticotropin(4-10) decreases body fat in humans. J Clin Endocrinol Metab 2001. 86(3):1144-1148.
43. Hallschmid M, Smolnik R, McGregor G, Born J, Fehm HL. Overweight humans are resistant to the weightreducing effects of melanocortin4-10. J Clin Endocrinol Metab 2006. 91(2):522-525.
44. Krude H, Biebermann H, Schnabel D, Tansek MZ, Theunissen P, Mullis PE, Gruters A. Obesity due to proopiomelanocortin deficiency: three new cases and treatment trials with thyroid hormone and ACTH4-10. J Clin Endocrinol Metab 2003. 88(10):4633-4640.
45. Schioth HB, Muceniece R, Wikberg JE. Characterisation of the melanocortin 4 receptor by radioligand binding. Pharmacol Toxicol 1996. 79(3):161-165.
46. Krishna R, Gumbiner B, Stevens C, Musser B, Mallick M, Suryawanshi S, Maganti L, Zhu H, Han TH, Scherer L, et al. Potent and selective agonism of the melanocortin receptor 4 with MK-0493 does not induce weight loss in obese human subjects: energy intake predicts lack of weight loss efficacy. Clin Pharmacol Ther 2009. 86(6):659-666.
47. Greenfield JR. Melanocortin signalling and the regulation of blood pressure in human obesity. J Neuroendocrinol 2011. 23(2):186-193.
48. Kawauchi H, Kawazoe I, Tsubokawa M, Kishida M, Baker BI. Characterization of melanin-concentrating hormone in chum salmon pituitaries. Nature 1983. 305(5932):321-323.
49. Bittencourt JC, Presse F, Arias C, Peto C, Vaughan J, Nahon JL, Vale W, Sawchenko PE. The melaninconcentrating hormone system of the rat brain: an immunoand hybridization histochemical characterization. J Comp Neurol 1992. 319(2):218-245.
50. Qu D, Ludwig DS, Gammeltoft S, Piper M, Pelleymounter MA, Cullen MJ, Mathes WF, Przypek R, Kanarek R, Maratos-Flier E. A role for melaninconcentrating hormone in the central regulation of feeding behaviour. Nature 1996. 380(6571):243-247.
51. Shimada M, Tritos NA, Lowell BB, Flier JS, Maratos-Flier E. Mice lacking melanin-concentrating hormone are hypophagic and lean. Nature 1998. 396(6712):670-674.
52. Saito Y, Nothacker HP, Wang Z, Lin SH, Leslie F, Civelli O. Molecular characterization of the melaninconcentrating-hormone receptor. Nature 1999. 400(6741):265-269.
53. Saito Y, Cheng M, Leslie FM, Civelli O. Expression of the melanin-concentrating hormone (MCH) receptor mRNA in the rat brain. J Comp Neurol 2001. 435(1):26-40.
54. Marsh DJ, Weingarth DT, Novi DE, Chen HY, Trumbauer ME, Chen AS, Guan XM, Jiang MM, Feng Y, Camacho RE, et al. Melanin-concentrating hormone 1 receptor-deficient mice are lean, hyperactive, and hyperphagic and have altered metabolism. Proc Natl Acad Sci U S A 2002. 99(5):3240-3245.
55. Hill J, Duckworth M, Murdock P, Rennie G, Sabido-David C, Ames RS, Szekeres P, Wilson S, Bergsma DJ, Gloger IS, et al. Molecular cloning and functional characterization of MCH2, a novel human MCH receptor. J Biol Chem 2001. 276(23):20125-20129.
56. Sailer AW, Sano H, Zeng Z, McDonald TP, Pan J, Pong SS, Feighner SD, Tan CP, Fukami T, Iwaasa H, et al. Identification and characterization of a second melanin-concentrating hormone receptor, MCH-2R. Proc Natl Acad Sci U S A 2001. 98(13):7564-7569.
57. Borowsky B, Durkin MM, Ogozalek K, Marzabadi MR, DeLeon J, Lagu B, Heurich R, Lichtblau H, Shaposhnik Z, Daniewska I, et al. Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist. Nat Med 2002. 8(8):825-830.
58. Takekawa S, Asami A, Ishihara Y, Terauchi J, Kato, K, Shimomura Y, Mori M, Murakoshi H, Suzuki N, Nishimura O, et al. T-226296: a novel, orally active and selective melanin-concentrating hormone receptor antagonist. Eur J Pharmacol 2002. 438(3):129-135.
59. Luthin DR. Anti-obesity effects of small molecule melaninconcentrating hormone receptor 1 (MCHR1) antagonists. Life Sci 2007. 81(6):423-440.
60. Bradley RL, Kokkotou EG, Maratos-Flier E, Cheatham B. Melanin-concentrating hormone regulates leptin synthesis and secretion in rat adipocytes. Diabetes 2000. 49(7):1073-1077.
61. Tadayyon M, Welters HJ, Haynes AC, Cluderay JE, Hervieu G. Expression of melanin-concentrating hormone receptors in insulin-producing cells: MCH stimulates insulin release in RINm5F and CRI-G1 cell-lines. Biochem Biophys Res Commun 2000. 275(2):709-712.
62. Ito M, Ishihara A, Gomori A, Matsushita H, Metzger JM, Marsh DJ, Haga Y, Iwaasa H, Tokita S, Takenaga N, et al. Mechanism of the anti-obesity effects induced by a novel melanin-concentrating hormone 1-receptor antagonist in mice. Br J Pharmacol 2010. 59(2):374-283.
63. AMRI, phase 1 data support the continued development of ALB-127158(a) as a potential treatment for obesity. 2011.
64. Lin LF, Armes LG, Sommer A, Smith DJ, Collins F. Isolation and characterization of ciliary neurotrophic factor from rabbit sciatic nerves. J Biol Chem 1990. 265(15):8942-8947.
65. Sendtner M, Arakawa Y, Stockli KA, Kreutzberg GW, Thoenen H. Effect of ciliary neurotrophic factor (CNTF) on motoneuron survival. J Cell Sci Suppl 1991. 15:103-109.
66. Stahl N, Farruggella TJ, Boulton TG, Zhong Z, Darnell JE Jr, Yancopoulos GD. Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors. Science 1995. 267(5202):1349-1353.
67. Lambert PD, Anderson KD, Sleeman MW, Wong V, Tan J, Hijarunguru A, Corcoran TL, Murray JD, Thabet KE, Yancopoulos GD, et al. Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity. Proc Natl Acad Sci U S A 2001. 98(8):4652-4657.
68. Gloaguen I, Costa P, Demartis A, Lazzaro D, Di Marco A, Graziani R, Paonessa G, Chen F, Rosenblum CI, Van der Ploeg LH, et al. Ciliary neurotrophic factor corrects obesity and diabetes associated with leptin deficiency and resistance. Proc Natl Acad Sci U S A 1997. 94(12):6456-6461.
69. Ettinger MP, Littlejohn TW, Schwartz SL, Weiss SR, McIlwain HH, Heymsfield SB, Bray GA, Roberts WG, Heyman ER, Stambler N, et al. Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study. JAMA 2003. 289(14):1826-1832.
70. Minamino N, Kangawa K, Matsuo H. Neuromedin U-8 and U-25: novel uterus stimulating and hypertensive peptides identified in porcine spinal cord. Biochem Biophys Res Commun 1985. 130(3):1078-1085.
71. Domin J, Ghatei MA, Chohan P, Bloom SR. Neuromedin U -a study of its distribution in the rat. Peptides 1987. 8(5):779-784.
72. Howard AD, Wang R, Pong SS, Mellin TN, Strack A, Guan XM, Zeng Z, Williams DL Jr, Feighner SD, Nunes CN, et al. Identification of receptors for neuromedin U and its role in feeding. Nature 2000. 406(6791):70-74.
73. Hanada T, Date Y, Shimbara T, Sakihara S, Murakami N, Hayashi Y, Kanai Y, Suda T, Kangawa K, Nakazato M. Central actions of neuromedin U via corticotropin-releasing hormone. Biochem Biophys Res Commun 2003. 311(4):954-958.
74. Novak CM, Zhang M, Levine JA. Sensitivity of the hypothalamic paraventricular nucleus to the locomotoractivating effects of neuromedin U in obesity. Brain Res 2007. 1169:57-68.
75. Hanada R, Teranishi H, Pearson JT, Kurokawa M, Hosoda H, Fukushima N, Fukue Y, Serino R, Fujihara H, Ueta Y, et al. Neuromedin U has a novel anorexigenic effect independent of the leptin signaling pathway. Nat Med 2004. 10(10):1067-1073.
76. Kowalski TJ, Spar BD, Markowitz L, Maguire M, Golovko A, Yang S, Farley C, Cook JA, Tetzloff G, Hoos L, et al. Transgenic overexpression of neuromedin U promotes leanness and hypophagia in mice. J Endocrinol 2005. 185(1):151-164.
77. Hainerova I, Torekov SS, Ek J, Finkova M, Borch-Johnsen K, Jorgensen T, Madsen OD, Lebl J, Hansen T, Pedersen O. Association between neuromedin U gene variants and overweight and obesity. J Clin Endocrinol Metab 2006. 91(12):5057-5063.
78. Wren AM, Small CJ, Abbott CR, Jethwa PH, Kennedy AR, Murphy KG, Stanley SA, Zollner AN, Ghatei MA, Bloom SR. Hypothalamic actions of neuromedin U. Endocrinology 2002. 143(11):4227-4234.
79. Peier AM, Desai K, Hubert J, Du X, Yang L, Qian Y, Kosinski JR, Metzger JM, Pocai A, Nawrocki AR, et al. Effects of Peripherally Administered Neuromedin U on Energy and Glucose Homeostasis. Endocrinology 2011. In press.
80. Budhiraja S, Chugh A. Neuromedin U: physiology, pharmacology and therapeutic potential. Fundam Clin Pharmacol 2009. 23(2):149-157.
81. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wren AM, Brynes AE, Low MJ, Ghatei MA, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002. 418(6898):650-654.
82. Abbott CR, Small CJ, Kennedy AR, Neary NM, Sajedi A, Ghatei MA, Bloom SR. Blockade of the neuropeptide Y Y2 receptor with the specific antagonist BIIE0246 attenuates the effect of endogenous and exogenous peptide YY(3-36) on food intake. Brain Res 2005. 1043(1-2):139-144.
83. Lin S, Shi YC, Yulyaningsih E, Aljanova A, Zhang L, Macia L, Nguyen AD, Lin EJ, During MJ, Herzog H, et al. Critical role of arcuate Y4 receptors and the melanocortin system in pancreatic polypeptide-induced reduction in food intake in mice. PLoS One 2009. 4(12):e8488.
84. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 1985. 89(5):1070-1077.
85. Ekblad E, Sundler F. Distribution of pancreatic polypeptide and peptide YY. Peptides 2002. 23(2):251-261.
86. Grandt D, Schimiczek M, Beglinger C, Layer P, Goebell H, Eysselein VE, Reeve JR Jr. Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1-36 and PYY 3-36. Regul Pept 1994. 51(2):151-159.
87. Medeiros MD, Turner AJ. Processing and metabolism of peptide-YY: pivotal roles of dipeptidylpeptidase-IV, aminopeptidase-P, and endopeptidase-24.11. Endocrinology 1994. 134(5):2088-2094.
88. Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, Ghatei MA, Bloom SR. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003. 349(10):941-948.
89. Asakawa A, Inui A, Yuzuriha H, Ueno N, Katsuura G, Fujimiya M, Fujino MA, Niijima A, Meguid MM, Kasuga M. Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology 2003. 124(5):1325-1336.
90. Batterham RL, Le Roux CW, Cohen MA, Park AJ, Ellis SM, Patterson M, Frost GS, Ghatei MA, Bloom SR. Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab 2003. 88(8):3989-3992.
91. Clark JT, Sahu A, Kalra PS, Balasubramaniam A, Kalra SP. Neuropeptide Y (NPY)-induced feeding behavior in female rats: comparison with human NPY ([Met17]NPY), NPY analog ([norLeu4]NPY) and peptide YY. Regul Pept 1987. 17(1):31-39.
92. Corp ES, McQuade J, Krasnicki S, Conze DB. Feeding after fourth ventricular administration of neuropeptide Y receptor agonists in rats. Peptides 2001. 22(3):493-499.
93. Clark JT, Kalra PS, Crowley WR, Kalra SP. Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats. Endocrinology 1984. 115(1):427-429.
94. Asakawa A, Inui A, Ueno N, Fujimiya M, Fujino MA, Kasuga M. Mouse pancreatic polypeptide modulates food intake, while not influencing anxiety in mice. Peptides 1999. 20(12):1445-1448.
95. Degen L, Oesch S, Casanova M, Graf S, Ketterer S, Drewe J, Beglinger C. Effect of peptide YY3-36 on food intake in humans. Gastroenterology 2005. 129(5):1430-1436.
96. Gantz I, Erondu N, Mallick M, Musser B, Krishna R, Tanaka WK, Snyder K, Stevens C, Stroh MA, Zhu H, et al. Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. J Clin Endocrinol Metab 2007. 92(5):1754-1757.
97. DeCarr LB, Buckholz TM, Milardo LF, Mays MR, Ortiz A, Lumb KJ. A long-acting selective neuropeptide Y2 receptor PEGylated peptide agonist reduces food intake in mice. Bioorg Med Chem Lett 2007. 17(7):1916-1919.
98. Adrian TE, Uttenthal LO, Williams SJ, Bloom SR. Secretion of pancreatic polypeptide in patients with pancreatic endocrine tumors. N Engl J Med 1986. 315(5):287-291.
99. Bellmann-Sickert K, Elling CE, Madsen AN, Little PB, Lundgren K, Gerlach LO, Bergmann R, Holst B, Schwartz TW, Beck-Sickinger AG. Long-acting lapidated analogue of human pancreatic polypeptide is slowly released into circulation. J Med Chem 2011. 54(8):2658-2667.
100. Pharma T. TM30339. 2011.
101. Pharma T. Obinepitide. 2011.
102. Pittner RA, Albrandt K, Beaumont K, Gaeta LS, Koda JE, Moore CX, Rittenhouse J, Rink TJ. Molecular physiology of amylin. J Cell Biochem 1994. 55(Suppl):19-28.
103. Sexton PM, Albiston A, Morfis M, Tilakaratne N. Receptor activity modifying proteins. Cell Signal 2001. 13(2):73-83.
104. Morley JE, Flood JF, Horowitz M, Morley PM, Walter MJ. Modulation of food intake by peripherally administered amylin. Am J Physiol 1994. 267(1 Pt 2):R178-R184.
105. Morris MJ, Nguyen T. Does neuropeptide Y contribute to the anorectic action of amylin? Peptides 2001. 22(3):541-546.
106. Whitehouse F, Kruger DF, Fineman M, Shen L, Ruggles JA, Maggs DG, Weyer C, Kolterman OG. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 2002. 25(4):724-730.
107. Ratner R, Whitehouse F, Fineman MS, Strobel S, Shen L, Maggs DG, Kolterman OG, Weyer C. Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets. Exp Clin Endocrinol Diabetes 2005. 113(4):199-204.
108. Badman MK, Flier JS. The adipocyte as an active participant in energy balance and metabolism. Gastroenterology 2007. 132(6):2103-2115.
109. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996. 334(5):292-295.
110. Roth JD, Roland BL, Cole RL, Trevaskis JL, Weyer C, Koda JE, Anderson CM, Parkes DG, Baron AD. Leptin responsiveness restored by amylin agonism in dietinduced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci U S A 2008. 105(20):7257-7262.
111. Trevaskis JL, Coffey T, Cole R, Lei C, Wittmer C, Walsh B, Weyer C, Koda J, Baron AD, Parkes DG, et al. Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanisms. Endocrinology 2008. 149(11):5679-5687.
112. Levin BE, Dunn-Meynell AA, Banks WA. Obesityprone rats have normal blood-brain barrier transport but defective central leptin signaling before obesity onset. Am J Physiol Regul Integr Comp Physiol 2004. 286(1):R143-R150.
113. Scarpace PJ, Matheny M, Tumer N. Hypothalamic leptin resistance is associated with impaired leptin signal transduction in aged obese rats. Neuroscience 2001. 104(4):1111-1117.
114. Trevaskis JL, Lei C, Koda JE, Weyer C, Parkes DG, Roth JD. Interaction of leptin and amylin in the long-term maintenance of weight loss in diet-induced obese rats. Obesity (Silver Spring) 2010. 18(1):21-26.
115. Chen HC, Roth JD, Schroeder BE, Weyer C. Role of islet-, gut-, and adipocyte-derived hormones in the central control of food intake and body weight: implications for an integrated neurohormonal approach to obesity pharmacotherapy. Curr Diabetes Rev 2008. 4(2):79-91.
116. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000. 407(6806):908-913.
117. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999. 402(6762):656-660.
118. Cowley MA, Smith RG, Diano S, Tschop M, Pronchuk N, Grove KL, Strasburger CJ, Bidlingmaier M, Esterman M, Heiman ML, et al. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron 2003. 37(4):649-661.
119. Hosoda H, Kojima M, Kangawa K. Biological, physiological, and pharmacological aspects of ghrelin. J Pharmacol Sci 2006. 100(5):398-410.
120. Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, Purnell JQ. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002. 346(21):1623-1630.
121. Wren AM, Small CJ, Ward HL, Murphy KG, Dakin CL, Taheri S, Kennedy AR, Roberts GH, Morgan DG, Ghatei MA, et al. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology 2000. 141(11):4325-4328.
122. Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, Murphy KG, Dhillo WS, Ghatei MA, Bloom SR. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001. 86(12): 5992.
123. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, Matsukura S. A role for ghrelin in the central regulation of feeding. Nature 2001. 409(6817):194-198.
124. Wang L, Saint-Pierre DH, Tache Y. Peripheral ghrelin selectively increases Fos expression in neuropeptide Y -synthesizing neurons in mouse hypothalamic arcuate nucleus. Neurosci Lett 2002. 325(1):47-51.
125. Tong J, Prigeon RL, Davis HW, Bidlingmaier M, Kahn SE, Cummings DE, Tschop MH, D'Alessio D. Ghrelin suppresses glucose-stimulated insulin secretion and deteriorates glucose tolerance in healthy humans. Diabetes 2010. 59(9):2145-2151.
126. Kobelt P, Helmling S, Stengel A, Wlotzka B, Andresen V, Klapp BF, Wiedenmann B, Klussmann S, Monnikes H. Anti-ghrelin Spiegelmer NOX-B11 inhibits neurostimulatory and orexigenic effects of peripheral ghrelin in rats. Gut 2006. 55(6):788-792.
127. Zorrilla EP, Iwasaki S, Moss JA, Chang J, Otsuji J, Inoue K, Meijler MM, Janda KD. Vaccination against weight gain. Proc Natl Acad Sci U S A 2006. 103(35):13226-13231.
128. Tschop M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001. 50(4):707-709.